Trials / Completed
CompletedNCT05325866
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bemarituzumab | Intravenous (IV) infusion. |
Timeline
- Start date
- 2022-09-23
- Primary completion
- 2026-01-28
- Completion
- 2026-01-28
- First posted
- 2022-04-13
- Last updated
- 2026-02-04
Locations
115 sites across 26 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Finland, France, Greece, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Romania, South Korea, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05325866. Inclusion in this directory is not an endorsement.